AR
NKGN

Advisory Research’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Advisory Research’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-43,088
Closed -$28.2K – 156
2024
Q4 		$28.2K Buy
+43,088
New +$17.6K ﹤0.01% 152

Other funds holding NKGN

DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
UOC
University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Advisory Research's NKGN Position: Q1 2025 in Review

Advisory Research sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2025, closing a stake of 43,088 shares — an estimated $28.2K sold.

Advisory Research first reported a position in NKGN in Q4 2024 and held it in 1 quarter. The position peaked at $28.2K in Q4 2024. 3 funds tracked by Wall St. Rank hold NKGN as of Q1 2025.

  • Advisory Research reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Advisory Research sold 43,088 NKGen Biotech, Inc. Common Stock shares in Q1 2025, an estimated $28.2K.
  • Advisory Research first reported a position in NKGen Biotech, Inc. Common Stock in Q4 2024 and held it in 1 quarter.
  • Advisory Research's NKGen Biotech, Inc. Common Stock position peaked at $28.2K in Q4 2024.
  • 3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2025.

Based on Advisory Research's 13F filing for Q1 2025, filed 14 May 2025.